NASDAQ: PSNLPersonalis Inc Stock
$4.60-0.06 (-1.29%)
Updated Aug 15, 2025
PSNL Price
$4.60
Fair Value Price
N/A
Market Cap
$407.91M
52 Week Low
$2.83
52 Week High
$7.79
P/E
-3.74x
P/B
2.14x
P/S
7.23x
PEG
N/A
Dividend Yield
N/A
Revenue
$80.32M
Earnings
-$91.32M
Gross Margin
31.4%
Operating Margin
-113.58%
Profit Margin
-113.7%
Debt to Equity
0.36
Operating Cash Flow
-$45M
Beta
2.11
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PSNL Overview
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PSNL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
PSNL
Ranked#39 of 42
Ranked#39 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $15.10 | A | |
| $15.74 | A | |
| $156.68 | B |
Be the first to know about important PSNL news, forecast changes, insider trades & much more!
PSNL News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PSNL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PSNL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PSNL is good value based on its book value relative to its share price (2.14x), compared to the US Diagnostics & Research industry average (3.86x)
P/B vs Industry Valuation
PSNL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PSNL due diligence checks available for Premium users.
Valuation
PSNL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.74x
Industry
23.48x
Market
35.99x
PSNL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.14x
Industry
3.86x
PSNL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PSNL's financial health
Profit margin
Revenue
$17.2M
Net Income
-$20.1M
Profit Margin
-116.6%
PSNL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PSNL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$258.7M
Liabilities
$67.9M
Debt to equity
0.36
PSNL's short-term assets ($193.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PSNL's short-term assets ($193.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PSNL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PSNL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.9M
Investing
-$4.4M
Financing
-$327.0k
PSNL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PSNL vs Diagnostic & Research Stocks
Personalis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.